149 related articles for article (PubMed ID: 36038734)
1. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
3. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
[TBL] [Abstract][Full Text] [Related]
4. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
Bai M; Yang L; Liao H; Liang X; Xie B; Xiong J; Tao X; Chen X; Cheng Y; Chen X; Feng Y; Zhang Z; Zheng W
Oncogene; 2018 Oct; 37(42):5666-5681. PubMed ID: 29921847
[TBL] [Abstract][Full Text] [Related]
5. NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB.
Cheng Y; Xie L; Xu Z; Hao M; Yang B; Shan W; Wang Y; Lv Q; Chen X
Cancer Gene Ther; 2022 Oct; 29(10):1452-1462. PubMed ID: 35388173
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
8. Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma.
Liu NT; Perng CL; Chou YC; Ko PS; Lin YJ; Lin YC; Chang CC; Wang YC; Shang HS; Chao TK
PLoS One; 2021; 16(11):e0259330. PubMed ID: 34731191
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
[TBL] [Abstract][Full Text] [Related]
11. Improving response to progestin treatment of low-grade endometrial cancer.
Baxter E; Brennan DJ; McAlpine JN; Mueller JJ; Amant F; van Gent MDJM; Huntsman DG; Coleman RL; Westin SN; Yates MS; Krakstad C; Quinn MA; Janda M; Obermair A
Int J Gynecol Cancer; 2020 Nov; 30(11):1811-1823. PubMed ID: 32381512
[TBL] [Abstract][Full Text] [Related]
12. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
[TBL] [Abstract][Full Text] [Related]
13. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
[TBL] [Abstract][Full Text] [Related]
14. Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells.
Ren B; Zhou J; Hu Y; Zhong R; Lv Q; Xie S; Li G; Yang B; Chen X; Zhu Y
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293372
[TBL] [Abstract][Full Text] [Related]
15. RNA-seq and ATAC-seq analysis of CD163
Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
[TBL] [Abstract][Full Text] [Related]
16. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance.
Chen X; Zhang Z; Feng Y; Fadare O; Wang J; Ai Z; Jin H; Gu C; Zheng W
Mod Pathol; 2009 May; 22(5):699-708. PubMed ID: 19287462
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
18. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
[TBL] [Abstract][Full Text] [Related]
19. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
20. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]